Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.57 |
| ▸ | PELP1 | Q8IZL8 | 1/20 | 0.57 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MYC | P01106 | 1/20 | 0.45 |
| ▸ | MAX | P61244 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11949145 | 0.88 | AR (0.58) | ARPELP1VCAM1AKR1C3AKR1C2 | |
| SCHEMBL1346767 | 0.88 | AR (0.61) | ARPELP1VCAM1AKR1C3AKR1C2 | |
| SCHEMBL8887657 | 0.88 | AR (0.58) | ARPELP1VCAM1AKR1C3AKR1C2 | |
| SCHEMBL222905 | 0.87 | AKR1C3 (0.61) | ARPELP1VCAM1AKR1C3AKR1C2 | |
| SCHEMBL8169431 | 0.87 | AR (0.60) | ARPELP1VCAM1AKR1C3AKR1C2 | |
| SCHEMBL24100292 | 0.86 | AR (0.56) | ARPELP1VCAM1AKR1C3AKR1C2 | |
| SCHEMBL221362 | 0.85 | AR (0.61) | ARPELP1VCAM1AKR1C3AKR1C2 | |
| SCHEMBL7618685 | 0.85 | AR (0.58) | ARPELP1VCAM1AKR1C3AKR1C2 | |
| SCHEMBL6870341 | 0.85 | AKR1C3 (0.56) | ARPELP1VCAM1AKR1C3AKR1C2 | |
| SCHEMBL7354751 | 0.85 | AR (0.55) | ARPELP1VCAM1AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247593-A1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | H. LUNDBECK A/S (DK) | 2009-10-01 | — | — | US | disclosed |
| EP-1803455-A1 | N-thiazol-2-yl-benzamide derivatives | H.Lundbeck A/S (DK) | 2007-07-04 | — | — | EP | disclosed |
| EP-1682129-B1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2007-02-21 | — | — | EP | disclosed |
| EP-1682129-A1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-07-26 | — | — | EP | disclosed |
| US-20060154974-A1 | N-thiazol-2-yl-benzamide derivatives | H. LUNDBECK A/S (DK) | 2006-07-13 | — | — | US | disclosed |
| WO-2005039572-A1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | H. LUNDBECK A/S (DK) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247593-A1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | ADORA2A, ADORA3, ADORA1 | AR 490/4885PELP1 4794/4885VCAM1 4270/4885 |
| US-20060154974-A1 | N-thiazol-2-yl-benzamide derivatives | ADORA2A, ADORA3, ADORA1 | AR 490/4885PELP1 4794/4885VCAM1 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.